Aim: This study evaluates reports on neuroleptic malignant syndrome (NMS) as an adverse event associated with the use of atypical antipsychotic agents (AAA) in Japan. We examined NMS occurrence following monotherapy and combination therapy with AAA in real clinical practice using the Japanese Adverse Drug Event Report database.
Neuroleptic malignant syndrome (NMS) is a rare but potentially lifethreatening idiosyncratic reaction that can occur in response to treatment with antipsychotic drugs. This syndrome is generally characterized by rigidity, tremor, fever, dysregulated sympathetic nervous system hyperactivity, alterations of mental status, leukocytosis, and creatine kinase elevation. 1 Furthermore, it can lead to patient death or permanent damages, such as neurological sequelae, if it is not promptly recognized or treated. 2, 3 The analysis of pooled data from 1966 to 1997 suggests that the incidence of NMS ranges from 0.2% to 3.2% of inpatients with psychiatric disorders receiving neuroleptics, 4 whereas the incidence has declined more recently to 0.01% to 0.02% as physicians have become increasingly aware of NMS and as newer neuroleptic agents have become available. 5 Antipsychotic drugs are used to treat serious mental health conditions, such as psychosis, as well as other emotional and mental conditions. They can be categorized into typical and atypical antipsychotic agents. 6 Typical antipsychotic agents (TAA) are known as 'first-generation antipsychotics,' whereas atypical antipsychotic agents (AAA) are commonly referred to as 'second-generation antipsychotics.' AAA have come to be widely used for the first-line treatment of schizophrenia 7, 8 and other psychiatric symptoms due to their higher effectiveness and safety than those of TAA. In Japan, risperidone was available in 1996 as the first AAA, whereas other AAA have been approved for sale since 2001. 9 NMS has been reported to be associated with the use of TAA. [9] [10] [11] [12] AAA are likely to be free from the risk of NMS because of their favorable pharmacodynamic profile. 13, 14 However, several studies have pointed out that AAA might also increase the risk of developing NMS. 15 Furthermore, the use of multiple medications, termed polypharmacy, has recently been recognized as an increasingly serious problem in antipsychotic therapy. [16] [17] [18] [19] Although some studies have discussed the efficacy of the combination of AAA, [20] [21] [22] there are limited reports on their adverse effects, such as insomnia, weight gain, and hyperprolactinemia. 21 In particular, the association between NMS and AAA in Japanese patients has not been studied.
Pharmacoepidemiological studies reflect drug safety and efficacy better than controlled clinical trials because the real-life use of drugs is very different from the controlled clinical trial environment in which drugs are tested prior to marketing. 23 In particular, pharmacovigilance is defined as the process of collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. 24 The assessment of benefit versus risk must begin during the preclinical evaluation of a medicinal product and must extend throughout its full life cycle.
Adverse event (AE) reporting is the cornerstone of pharmacovigilance and, therefore, it is closely supervised by regulatory authorities. 25 Suspected adverse drug reactions are systematically collected through the spontaneous reporting system. Although several methods are available for conducting drug safety studies, the spontaneous reporting system is one method that is used throughout the life of a drug and is currently used in most developed and many developing countries. In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) created the Japanese Adverse Drug Event Report (JADER) database for organizing spontaneous adverse drug reaction reports in Japan and it has been freely available for download through their website since April 2012. 26 In the present study, we assessed reports on NMS associated with the use of AAA in Japan from a pharmacovigilance point of view using spontaneous adverse drug reaction reports in the JADER database. In particular, we focused on the use of AAA without TAA, and investigated reports on NMS associated with AAA monotherapy and combination therapy using two AAA without TAA.
Methods Database
The JADER is a database of post-marketing surveillance and spontaneous reports from physicians, pharmacists, other health-care professionals, and patients, collected by PMDA as a Japanese regulatory authority established by the Ministry of Health, Labour and Welfare in 2004. 27, 28 This database is used for Japanese pharmacovigilance, and it is similar to the database of the US Food and Drug Administration Adverse Event Reporting System (FAERS) in the USA. The JADER database contains over 440 000 AE cases occurring specifically in Japan reported after April 2004. The source of the database is compliant with the International Conference for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines, and the databases basically adheres to ICH-standardized AE information guidelines and provides the main items for each AE case, such as age, sex, medicinal product/substance name, nature of AE, and case outcome. Multiple drug names in polypharmacy, multiple adverse reactions, and multiple medical histories are allowed in a case, and the contribution of the AE of medications provided has been classified into three categories: 'suspected medicine,' 'concomitant medicine,' and 'interaction.' 29, 30 The JADER database can be downloaded from the website of the PMDA (www.pmda.go.jp), and it has been fully anonymized by the regulatory authority. It consists of four datasets in csv format: patient demographic information (DEMO.csv), drug information (DRUG.csv), AE information (REAC.csv), and primary disease information (HIST.csv). These tables can be connected using the case ID number.
Materials and definitions
Data reported from April 2004 through March 2017 in JADER were extracted for our analysis.The drug names were categorized by standard commodity classification. 31 A case with multiple drug names in polypharmacy regardless of the categories of the contribution of the AE of medications was defined as a combination therapy with these drugs. Ten currently available AAA (aripiprazole, asenapine maleate, blonanserin, clozapine, olanzapine, paliperidone, perospirone, quetiapine, risperidone, and zotepine) were considered in this study; zotepine was included here based on a previous study. 32 In addition, we considered haloperidol, a TAA, as a reference drug because its use is a known risk factor for the occurrence of NMS.
11,33 Therefore, we analyzed reports of patients treated with: AAA monotherapy, without TAA regardless of the use of other drugs (P1); and patients treated with two AAA, without TAA regardless of the use of other drugs (P2). As a reference group, we considered reports of patients treated with haloperidol monotherapy, without other AAA or TAA regardless of the use of other drugs (P3).
The AE of NMS was identified by two kinds of reports: (i) 'neuroleptic malignant syndrome' in preferred terms (PT-NMS) defined in the Medical Dictionary for Regulatory Activities (MedDRA); and (ii) 'neuroleptic malignant syndrome' in the standardized MedDRA Query (SMQ-NMS), where the standardized Med-DRA Query is constructed by groups of terms from one or more MedDRA system organ classes related to the defined medical condition or area of interest. They were coded according to the MedDRA version 19.1.
Statistical analysis
We set the outcome as the inclusion of NMS as an adverse reaction in the reports. First, we summarized reports of NMS associated with the use of AAA in the database. Second, we calculated the crude and sex-and age-adjusted odds ratios (OR) of NMS occurrence after monotherapy with AAA relative to those after haloperidol monotherapy using a multiple logistic regression model for (P1) and (P3) reports. Age was categorized as 0-20, 20-50, 50-70, >70 years, and unknown/other/missing. Reports with no sex included were treated as 'sex unknown' in the analysis. Third, we calculated sex-and age-adjusted OR of NMS occurrence after combinaton therapy comprising two AAA relative to those after haloperidol monotherapy using the multiple logistic regression for (P2) and (P3) reports. The OR was derived from coefficients of individual terms of two AAA after adding their interaction terms, where the interaction terms were selected using a stepwise method based on likelihood ratio test with α = 0.2. The significance level was set at P < 0.05 for all statistical analyses. Table 1 summarizes spontaneous reporting data reported from April 2004 through March 2017 in JADER. Among 445 706 cases, 47 441 (10.6%) and 15 330 (3.4%) were treated with a psychotropic and one or more AAA, respectively. The number of cases that used a single AAA without a TAA was 8551/15 330 (55.8%), whereas 1955/15 330 (12.8%) were reported in patients treated with two AAA without any TAA. The maximum numbers in both cases were reported following treatment with risperidone. However, only 565 cases were reported in patients treated with three or more AAA without TAA.
Results

Summary of NMS reports in JADER
NMS was reported in 2527 cases (0.6%) as PT-NMS and 3266 cases (0.7%) as SMQ-NMS. Most NMS cases, 2106/47 441 (4.4%) as PT-NMS and 2565/47 441 (5.4%) as SMQ-NMS, were reported in psychotropic users. However, the proportions of NMS reports in the cases of AAA users were 1303/15 330 (8.5%) as PT-NMS and 1409/15 330 (9.2%) as SMQ-NMS. Furthermore, the proportions of NMS reports in patients using single AAA without TAA were 495/8551 (5.8%) as PT-NMS and 563/8551 (6.6%) as SMQ-NMS, whereas the proportions in patients using two AAA without TAA were 170/1955 (8.7%) as PT-NMS and 180/1955 (9.2%) as SMQ-NMS.
A total of 1805 cases reported the use of the reference drug haloperidol without AAA, whereas 1297 cases reported the use of haloperidol as a single TAA without other AAA or TAA. In cases of haloperidol use without AAA, 284/1805 (15.7%) and 293/1805 (16.2%) reported PT-NMS and SMQ-NMS, respectively. In cases of haloperidol use without other AAA or TAA, 174/1297 (13.4%) and 179/1297 (13.8%) reported PT-NMS and SMQ-NMS, respectively. These proportions were higher than those reporting the use of any single AAA.
Patient sex and age data are shown in Table S1 . NMS reports in male patients were greater than or equal to those in female patients, and the proportions of NMS among all cases varied among different age groups (P < 0.05).
OR of NMS after monotherapy with an AAA without TAA Table 2 shows estimated crude and sex-and age-adjusted OR of PT-NMS and SMQ-NMS after monotherapy with each AAA without TAA relative to those after monotherapy with haloperidol without other AAA or TAA. In these analyses, we excluded asenapine maleate because NMS was not observed in seven reports of adverse drug reactions associated with asenapine maleate monotherapy. Most AAA had OR for NMS occurrence lower than 1.0 of haloperidol monotherapy. In particular, clozapine had a very small OR of 0.08 (adjusted) for both PT-NMS and SMQ-NMS with statistical significance (P < 0.001). However, the adjusted OR of blonanserin were estimated as 1.55 (P = 0.045) for PT-NMS and 1.49 (P = 0.069) for SMQ-NMS.
OR of NMS after combination therapy with two AAA without TAA Estimated sex-and age-adjusted OR of PT-NMS and SMQ-NMS after combination therapy with two AAA without TAA relative to those after haloperidol monotherapy without other AAA or TAA are shown in Tables 3 and 4 , respectively. Furthermore, asenapine maleate was excluded from the analysis. The multiple logistic regression models used in these analyses are shown in Table S2 . In these models, the same seven interaction terms were selected for both PT-NMS and SMQ-NMS.
For both PT-NMS and SMQ-NMS, most combinations of two AAA had OR for NMS occurrence lower than 1.0 of haloperidol monotherapy. The OR after combination therapy with clozapine and another AAA were particularly low. OR after combination therapy with blonanserin and another AAA were lower than those after blonanserin monotherapy.
Although PT-NMS OR were 0.29, 0.39, and 0.63 after monotherapy with quetiapine, risperidone, and zotepine, respectively, they significantly increased to 5.15 and 5.24 after combination therapy with quetiapine and zotepine, and risperidone and zotepine, respectively. SMQ-NMS OR were similar for these combinations at 5.11 and 5.12 after combination therapy with quetiapine and zotepine, and risperidone and zotepine, respectively.
Discussion
In this study, we summarized reports of NMS as an adverse reaction in JADER and found that most cases of NMS were associated with the use of psychotropic agents. In addition, NMS occurred in male and female patients and was distributed across all age groups, which is consistent with previous reports. 34 Approximately half of the NMS cases were associated with the use of one or more AAA, and half were reported in patients without TAA. It is possible that NMS could be reported in combination with other clinical events; however, there were only slight differences between PT-NMS and SMQ-NMS cases, as the latter also included related syndromes. For instance, in cases of monotherapy with an AAA without TAA, SMQ-NMS cases were higher than PT-NMS cases were by only 68 cases, and 59 of these were based on serotonin syndrome. Other cases included pyrexia, rhabdomyolysis, depressed consciousness, and muscle rigidity.
We focused on the difference in NMS occurrence among AAA in monotherapy and combination therapy. The number of antipsychotic agents used is known to be correlated with the risk of NMS, 11 and our results showed a higher proportion of NMS in patients using two AAA than in those using single AAA. On the other hand, the influence of each AAA on NMS occurrence was assumed to differ between individual treatment and combination therapy. Therefore, we analyzed the data of patients treated with AAA monotherapy and those with two AAA separately.
We evaluated the OR of NMS occurrence based on the proportion of NMS among all adverse reaction reports for each AAA without TAA relative to those after haloperidol monotherapy without other AAA or TAA. Haloperidol is known as a TAA with risk for causing NMS. Although the OR cannot be interpreted as a measure of risk for NMS directly, it could imply a relative impact of NMS compared to all adverse reactions possibly caused by the drug. For example, OR for NMS occurrence associated with clozapine were lower than those associated with other AAA. It is known that clozapine induces adverse reactions involving agranulocytosis and ileus, 35 whereas these are rarely reported for other AAA. We also found in JADER that these events are frequently reported in association with clozapine use; thus, the main adverse reactions of clozapine were those other events, rather than NMS.
On the other hand, we identified drugs with a higher risk of causing NMS based on the large OR of NMS occurrence associated with their use. Differences between the OR of NMS occurrence associated with AAA monotherapy and those associated with combination therapy could be evaluated as interaction effects associated with combination therapy on NMS occurrence. The results of our study indicated that monotherapy with most AAA had lower OR for NMS occurrence than haloperidol monotherapy. This is consistent with previous reports that AAA are likely to be free from the risk of NMS because of their favorable pharmacodynamics profile. 13, 14, 32 Moreover, OR associated with most combinations of two AAA were lower than those associated with haloperidol monotherapy, suggesting that combination therapy with two AAA does not excessively increase the risk of NMS.
However, monotherapy with blonanserin yielded the highest OR for NMS occurrence among other AAA, and it was higher than 1.0 of haloperidol monotherapy. This could be because blonanserin has a different receptor binding profile from those of other antipsychotic drugs. Specifically, it has an antagonistic effect on both dopamine D 2 and serotonin 5-HT 2A receptors causing a blockade in vitro, thereby increasing the risk of NMS because the occurrence of NMS is correlated with D 2 receptor blockade. 11, 36 Combination therapy with blonanserin and another AAA yielded lower OR than blonanserin monotherapy. Typically, when antipsychotics are used in combination, individual doses for treatment are adjusted to maintain the chlorpromazine-equivalent dose of the combination. 20 This might relatively reduce the risk of blonanserininduced NMS compared to blonanserin monotherapy. Although such adjustments of dose could also be used in combination therapy with other AAA, they have a higher affinity for the serotonin 5-HT 2A receptor than for the dopamine D 2 receptor, which is correlated with the occurrence of NMS; this indicates an opposing profile to that of blonanserin. This observation suggests that the dose adjustment in combination therapy with other AAA might not largely affect the risk of NMS, and our results indicate slight differences between the OR of monotherapy and combination therapies except for blonanserin. However, we could not confirm this in the present study because of the lack of detailed information from the present reports in JADER and, therefore, we will focus on this aspect in our future research studies.
Combinations of quetiapine and zotepine, and risperidone and zotepine yielded extensively higher OR for NMS occurrence than haloperidol monotherapy did, despite the lower OR associated with their monotherapies. This might have been caused by the antiparkinsonian effects of these combinations. Antiparkinsonian agents are known risk factors for NMS. 11 The proportions of cases in which antiparkinsonian agents were used along with each of the above combinations, other combinations of two AAA, and haloperidol were 50%, 20%, and 15%, respectively. In patients treated with a combination of any two AAA, the number of reports of NMS, 55/472 (11.7%), was significantly higher (P = 0.009) when antiparkinsonian agents were also used in these patients than when no antiparkinsonian agents were administered, 115/1483 (7.8%). However, the proportion of reports of NMS associated with the use of the above combinations was markedly higher (approximately 50%) than that associated with the use of the combinations with antiparkinsonian agents, suggesting that the above combinations may also cause interactions that increase the risk of NMS.
We analyzed adverse reaction reports in JADER and spontaneous reports in this database were used to evaluate the association between NMS occurrence and the use of AAA in this study. It should be noted that the spontaneous report is not a random sample. On the other hand, because of the large size of this database, we could analyze over 2000 and 1300 NMS cases associated with the use of psychotropic agents and AAA, respectively. Previous studies included only 86 15 to 423 cases. 9 A large patient sample size is required to assess relations between drug use and AE; accordingly, a large database facilitates the gathering of information on rare AE, such as NMS. Furthermore, this database, comprising spontaneous reports, can provide information from real-life clinical practice as opposed to clinical trials, where vulnerable individuals are excluded, and treatment duration is limited. 23 In our study, we evaluated patients older than 70 years and those treated with concomitant medications. In particular, the analysis of this database yielded data on NMS occurrence due to both AAA monotherapy and combination therapy with two AAA.
Our study has several limitations. In the present study, we evaluated NMS occurrence only in Japanese patients using JADER. The association between NMS and each AAA or their combination was not evaluated in patients of other ethnicities from other countries. Further evaluation should be performed using other databases, such as the FAERS, paying attention to database profile variations in drug safety assessments. 28 We could not account for the detailed characteristics of patients, such as weight, height, and information on treatment exposure (daily total dose or cumulative dose), because these data were missing in more than half of the reports, regardless of whether they were items in the database. Moreover, clinical information, such as duration from treatment start or treatment switch, and disease severity, could not be evaluated because they were not included in items to be reported. Asenapine maleate was approved for sale only in 2016 in Japan and, therefore, it was excluded from our analysis because of the small number of cases at the time of analysis.
In conclusion, monotherapy and combination therapy with most AAA without TAA are not likely to cause NMS as an adverse reaction compared to haloperidol monotherapy. However, we found that blonanserin monotherapy and combination therapies with quetiapine and zotepine, and risperidone and zotepine, possibly increased the report of NMS. Treatment with AAA, including their combinations, is an important management option for patients with schizophrenia. 21 Our results could be useful information for the treatment of mental disorders in real clinical practice, though further research with more data are needed to clarify this. Author contributions T.A. and K.T. conceived and designed the study. T.A. analyzed the data and drafted the article. All authors critically reviewed the manuscript, and approved the final version of this manuscript. 
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